Main Results of Clinical Study
| Parameter | Study group (n = 115) | Control group (n = 230) | P |
| Mean age (y) | 59 | 58 | 1.0 |
| Matching criteria | |||
| Microorganism SAB | 73 (64%) | 146 (64%) | 1.0 |
| SSB | 30 (26%) | 60 (26%) | 1.0 |
| Enterococcus | 12 (10%) | 24 (10%) | 1.0 |
| Community acquisition | 70% | 68% | 0.71 |
| Treatment delay > 48 h | 27% | 45% | 0.01 |
| Fever > 72 h | 46% | 37% | 0.13 |
| Portal of entry unknown | 52% | 46% | 0.30 |
| Central venous catheter not removed > 48 h | 5% | 8% | 0.50 |
| Blood cultures > 72 h* | 16% | 6% | <0.01 |
| Immunosuppression | 22% | 17% | 0.30 |
| Known malignancy | 14% | 17% | 0.53 |
| Echocardiography performed | 83% | 29% | <0.01 |
| Metastatic foci (no. of patients) | 68% | 36% | <0.01 |
| Endocarditis | 18% | 8% | 0.01 |
| Relapse of infection | 2.6% | 7.4% | 0.09 |
| Overall mortality | 19% | 32% | <0.01 |
| Median treatment days | |||
| Metastatic infection present | 45 | 36 | <0.01 |
| Metastatic infection absent | 14 | 14 | 0.38 |
| Length of hospital stay | |||
| Metastatic infection present | 27 | 28 | 0.51 |
| Metastatic infection absent | 14 | 14 | 0.61 |
↵* Not routinely obtained in control group.